FindTrial
Sign In

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05505838
Enrollment
Unknown
Registered
2022-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ATTR Amyloidosis With Cardiomyopathy, Transthyretin-mediated Amyloidosis With Cardiomyopathy

Keywords

RNAi therapeutic, Amyloidosis, Cardiomyopathy, TTR, Transthyretin

Brief summary

The objective of the study is to assess the long-term safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy as assessed by a review of adverse events (AEs).

Detailed description

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided.

Interventions

DRUGPatisiran

Patisiran administered by intravenous (IV) infusion

Sponsors

Alnylam Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* Documented diagnosis of ATTR amyloidosis with cardiomyopathy, classified as either hATTR amyloidosis with cardiomyopathy or wtATTR amyloidosis with cardiomyopathy; AND * Had an inadequate response to or could not tolerate standard of care, in the opinion of the investigator. * Is not eligible for on-label use of commercial patisiran in the opinion of the investigator.

Exclusion criteria

* New York Heart Association (NYHA) Class IV * NYHA Class III AND ATTR amyloidosis disease Stage 3 (defined as both N-terminal prohormone B-type natriuretic peptide (NT-proBNP) \>3000 ng/L and estimated glomerular filtration rate \[eGFR\] \<45 ml/min/1.73 m\^2). \[Gillmore 2018\] * Current or future participation in another investigational device or drug study, scheduled to occur during this study, or has received an investigational agent or device within 30 days (or 5 half-lives of the investigational drug, whichever is longer) prior to dosing (Day 1). Patients who have previously participated in a gene therapy trial for hATTR amyloidosis. * Patients currently enrolled in, eligible for inclusion in, or who have dropped out of an ongoing interventional (therapeutic) clinical trial related to ATTR amyloidosis.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026